Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.
The US subsidiary first submitted the sNDA on August 31, but the FDA turned down the application on the grounds that the application did not conform to the FDA standard. The resubmitted sNDA is expected to be accepted by the FDA within 60 days.
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Dec 24, 2005|
|Previous Article:||Epson Toyocom Announces Smallest-Class VCXO for Mobile Handsets with Support for Terrestrial Digital Broadcasts.|
|Next Article:||Sosei, HRA, and Sandoz/Hexal Australia to Conclude Sublicensing Agreement for "Morning After Pill" SOH-075.|